Position in ANIP
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$19,366,794
+$1,124,192 QoQ
Shares Held
233,955
-1.4% QoQ
Ownership
1.02%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#27
of 303 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANIP Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026NOMURA HOLDINGS INC holds $203,047,916 across 12 Drug Manufacturers - Specialty & Generic names. ANIP ranks #5 (9.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRLV |
Trulieve Cannabis Corp.
|
5,065,849 | $49,797,295 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,124,772 | $38,107,275 | |
| 3 | GLAS |
Glass House Brands Inc.
|
2,283,439 | $29,684,707 | |
| 4 | ZTS |
Zoetis Inc.
|
400,277 | $28,763,903 | |
| 5 | ANIP |
Ani Pharmaceuticals Inc
This page
|
233,955 | $19,366,794 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
270,724 | $17,312,799 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
16,753 | $9,077,277 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
175,160 | $6,072,797 |
All Filings in ANIP
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,366,794 | 233,955 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $18,242,602 | 237,225 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $17,677,428 | 223,935 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $17,909,448 | 195,518 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $2,852,273 | 43,713 | Shares | Defined | 2025-08-18 | |
| 2025-03-31 | $14,539,933 | 217,176 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $11,823,231 | 213,879 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $12,565,827 | 210,624 | Shares | Defined | 2025-01-13 | |
| No filing history on record for this holder in this stock. | ||||||